Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25358124 | 0.88 | MRGPRX4 (0.50) | LMNAHPGDPTPN1PTPN6PTPN2 | |
| SCHEMBL427348 | 0.81 | MRGPRX4 (0.50) | LMNAHPGDPTPN1PTPN6PTPN2 | |
| SCHEMBL16096871 | 0.79 | LMNA (0.50) | LMNAHPGDPTPN1PTPN6PTPN2 | |
| SCHEMBL30141003 | 0.79 | LMNA (0.56) | LMNAHPGDMRGPRX4FFAR4USP2 | |
| SCHEMBL24983669 | 0.79 | LMNA (0.56) | LMNAHPGDMRGPRX4FFAR4USP2 | |
| SCHEMBL13662895 | 0.78 | LMNA (0.58) | LMNAHPGDFFAR4USP2ALDH1A1 | |
| SCHEMBL9756722 | 0.78 | LMNA (0.52) | LMNAHPGDPTPN1PTPN6PTPN2 | |
| SCHEMBL1305662 | 0.78 | HPGD (0.57) | LMNAHPGDUSP2ALDH1A1TSHR | |
| SCHEMBL31291004 | 0.77 | RXRA (0.52) | PTPN1PTPN6PTPN2MRGPRX4LRRK2 | |
| SCHEMBL25358389 | 0.77 | RXRA (0.52) | PTPN1PTPN6PTPN2MRGPRX4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319101-B2 | COMT inhibitors for the treatment of depression and impaired cognition | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319101-B2 | COMT inhibitors for the treatment of depression and impaired cognition | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319101-B2 | COMT inhibitors for the treatment of depression and impaired cognition | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1697394-B1 | COMT INHIBITORS | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1697394-B1 | COMT INHIBITORS | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1697394-A2 | COMT INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058228-A2 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058228-A2 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | COMT, MAOB, TPH1 | LMNA 4305/4885HPGD 544/4885PTPN1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.